^
    Back
    Association details:
    Biomarker:CERS4 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Pharmacol Res
    Title:

    CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer

    Excerpt:
    ...CERS4 was positively correlated with the survival of patients with NSCLC, and the patients with high CERS4 expression demonstrated longer survival (P = 0.00057, Fig. 2A and B).
    DOI:
    https://doi.org/10.1016/j.phrs.2023.106850